Patents Assigned to P2D, Inc.
  • Thalidomide analogs
    Patent number: 8853253
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: October 7, 2014
    Assignee: P2D, Inc.
    Inventors: Nigel H. Greig, Harold Holloway, Tony Giordano, Qian-sheng Yu, William D. Figg
  • Thalidomide analogs
    Patent number: 8546430
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: October 1, 2013
    Assignee: P2D, Inc.
    Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
  • 4?,4?-substituted 3?-(diphenylmethoxy) tropane analogs for treatment of mental disorders
    Patent number: 7361667
    Abstract: The present invention describes a method for the treatment of attention deficit hyperactivity disorder (ADHD), conduct disorder, alcohol addiction, tobacco addiction, nicotine addiction, parkinsonism including Parkinson's disease, female and male orgasmic disorders, female and male sexual arousal disorders, hypoactive sexual desire disorder, and disorders characterized by anxiety and/or depression. In this method, a therapeutically effective, nontoxic dose of a 4?,4?-substituted 3?-(diphenylmethoxy) tropane analog or a pharmaceutically acceptable salt thereof is administered to the patient in need of such treatment.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: April 22, 2008
    Assignee: P2D, Inc.
    Inventor: Frank P. Zemlan